BridgeBio Pharma
$49.139876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$49.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.66 (+1.36%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours
Why Robinhood?
You can buy or sell BBIO and other stocks, options, and ETFs commission-free!
About BBIO
BridgeBio Pharma, Inc. Common Stock, also called BridgeBio Pharma, is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA. The listed name for BBIO is BridgeBio Pharma, Inc. Common Stock.
CEO
Neil Kumar
Employees
248
Headquarters
Palo Alto, California
Founded
2015
Market Cap
6.02B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
710.96K
High Today
$50.09
Low Today
$48.54
Open Price
$48.96
Volume
242.50K
52 Week High
$50.09
52 Week Low
$14.23
Collections
Analyst Ratings
91%
of 11 ratings
Buy
91%
Hold
9%
Sell
0%
BBIO Earnings
-$3.46
-$2.31
-$1.15
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 2, Pre-Market